Peapack Gladstone Financial Corp Sells 44,429 Shares of Zoetis Inc. $ZTS

Peapack Gladstone Financial Corp lowered its stake in Zoetis Inc. (NYSE:ZTS) by 60.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 29,173 shares of the company’s stock after selling 44,429 shares during the period. Peapack Gladstone Financial Corp’s holdings in Zoetis were worth $3,671,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ZTS. Global Wealth Strategies & Associates bought a new position in Zoetis in the fourth quarter valued at approximately $25,000. Lodestone Wealth Management LLC bought a new position in Zoetis in the fourth quarter valued at approximately $30,000. KERR FINANCIAL PLANNING Corp bought a new position in Zoetis in the third quarter valued at approximately $31,000. Holos Integrated Wealth LLC bought a new position in Zoetis in the fourth quarter valued at approximately $32,000. Finally, Elyxium Wealth LLC bought a new position in Zoetis in the fourth quarter valued at approximately $32,000. Institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling

In other Zoetis news, Director Paul Bisaro acquired 2,000 shares of the company’s stock in a transaction on Wednesday, May 13th. The shares were purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Frank A. Damelio acquired 6,650 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was acquired at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the purchase, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 11,650 shares of company stock worth $886,384. Insiders own 0.22% of the company’s stock.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms issued reminders and deadline notices tied to an ongoing securities fraud class action against Zoetis, alleging investors were harmed by false or misleading statements during the Jan. 14, 2025 to May 6, 2026 period. These headlines can weigh on sentiment because they raise legal overhang and potential financial/reputational risk.
• Negative Sentiment: Zoetis was reportedly downgraded after a steep broader market selloff, signaling weakening near-term sentiment from Wall Street and adding to pressure on the stock.
• Negative Sentiment: A bearish article highlighted lawsuits challenging the company’s companion-animal outlook, suggesting investors may be questioning growth assumptions for a key business segment.
• Neutral Sentiment: Zoetis presented at the 46th Annual William Blair Growth Stock Conference, which may help investors gauge management’s outlook and strategy, but no major new catalyst was highlighted in the transcript headline.
• Neutral Sentiment: One valuation-oriented piece argued Zoetis could be a deep-value opportunity with significant upside, which may support longer-term sentiment but is unlikely to outweigh today’s legal and rating-related headlines.

Zoetis Stock Performance

Shares of ZTS stock opened at $76.42 on Wednesday. The company’s fifty day simple moving average is $103.52 and its 200-day simple moving average is $116.71. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The firm has a market cap of $32.04 billion, a PE ratio of 12.67, a P/E/G ratio of 1.27 and a beta of 0.75. Zoetis Inc. has a 12 month low of $72.38 and a 12 month high of $172.23.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.Zoetis’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts expect that Zoetis Inc. will post 6.89 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is presently 35.16%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. cut their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. William Blair reissued an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Argus reissued a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Finally, Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Six equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $133.92.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.